Bioventus

120 articles about Bioventus

• Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results

  3/12/2024

  Bioventus Inc., a global leader in innovations for active healing, announced fourth quarter and full-year financial results for the year ended December 31, 2023, and provided its financial guidance for full-year 2024.

• Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024

  3/4/2024

  Bioventus Inc. today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 12, 2024.

• Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole

  1/12/2024

  Bioventus Inc. announced the issuance on January 11, 2024 of previously disclosed inducement equity awards to Robert Claypoole in connection with this appointment as President and Chief Executive Officer, and Principle Executive Officer of the Company.

• Bioventus Names Robert Claypoole as President and Chief Executive Officer

  12/19/2023

  Bioventus Inc., a global leader in innovations for active healing, announced that its Board of Directors has appointed Robert Claypoole as Bioventus’ President and Chief Executive Officer and a member of its Board of Directors, effective January 10, 2024.

• Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance

  11/7/2023

  Bioventus Inc., a global leader in innovations for active healing, reported financial results for the three and nine months ended September 30, 2023.

• Bioventus to Present at the Cantor Global Healthcare Conference

  9/20/2023

  Bioventus Inc. announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 1:50 p.m. ET.

• Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

  9/6/2023

  Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Tony Bihl, interim chief executive officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 13, 2023, at 8:50 a.m. ET.

• Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance

  8/8/2023

  Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023.

• Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference

  8/4/2023

  Bioventus Inc. will present at the Canaccord Genuity Global Growth Conference on Thursday, August 10, 2023, at 8:00 a.m. ET.

• Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023

  8/1/2023

  Bioventus Inc., a global leader in innovations for active healing, announced that it will report financial results for the second quarter of fiscal year 2023 before the market opens on Tuesday, August 8, 2023.

• Bioventus Completes Divestiture of its Wound Business

  5/23/2023

  Bioventus Inc., a global leader in innovations for active healing, announced that it has successfully completed the divestiture of its Wound business, including the skin substitutes TheraSkin and TheraGenesis, to LifeNet Health.

• Bioventus Reports First Quarter Financial Results

  5/16/2023

  Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three months ended April 1, 2023.

• Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023

  5/15/2023

  Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report financial results for the first quarter of fiscal year 2023 after the market closes on Tuesday, May 16, 2023.

• Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023

  5/11/2023

  Bioventus Inc., a global leader in innovations for active healing, announced the Company plans to file Form 12b-25, Notification of Late Filing, for its Quarterly Report on Form 10-Q for the period ended April 1, 2023, on May 11, 2023.

• Bioventus Announces Divestiture of its Wound Business

  5/10/2023

  Bioventus Inc., a global leader in innovations for active healing, announced that it has signed a definitive agreement to sell its Wound business, including the skin substitutes TheraSkin and TheraGenesis, to LifeNet Health.

• Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023

  5/3/2023

  Bioventus Inc. today announced that it will report financial results for the first quarter of fiscal year 2023 before the market opens on Thursday, May 11, 2023.

• Bioventus Announces CEO Leadership Change

  4/5/2023

  Bioventus Inc., a global leader in innovations for active healing, announced that Ken M. Reali has stepped down as Chief Executive Officer and as a member of the Board of Directors.

• Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results

  3/31/2023

  Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the year ended December 31, 2022.

• Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

  3/31/2023

  Bioventus Inc. announced that it has entered into an Amendment No. 4 to the Credit and Guaranty Agreement, between the Company, Wells Fargo Bank, National Association as Administrative Agent and Collateral Agent, and the Lenders from time to time party thereto, dated as of December 6, 2019 and as amended on August 29, 2021, October 29, 2021 and July 11, 2022.

• Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023

  3/29/2023

  Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report financial results for the fourth quarter of fiscal year 2022 before the market opens on Friday, March 31, 2023, rather than as previously announced to allow additional time to complete its financial statements.